| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Cancer/testis antigen 98; CT98; DKFZp686F1078; hKOC; IF2B3_HUMAN; IGF II mRNA binding protein 3; IGF-II mRNA-binding protein 3; IGF2 mRNA binding protein 3; IGF2 mRNA-binding protein 3; IGF2BP3; IMP 3; IMP-3; Insulin like growth factor 2 mRNA binding protein 3; Insulin-like growth factor 2 mRNA-binding protein 3; KH domain containing protein overexpressed in cancer; KH domain-containing protein overexpressed in cancer; KOC 1; KOC1; VICKZ 3; VICKZ family member 3; VICKZ3. |
| Entrez GeneID | 10643 |
| WB Predicted band size | Calculated MW: 64 kDa; Observed MW: 69 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human IMP3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IMP3抗体的3篇参考文献，按文献名称、作者及摘要内容概括列出：
1. **"IMP3 is a novel biomarker for triple-negative breast cancer"**
- **作者**: Li D, et al.
- **摘要**: 研究通过免疫组化分析IMP3在乳腺癌中的表达，发现IMP3抗体检测可有效区分三阴性乳腺癌亚型，并与患者预后不良相关。
2. **"IMP3 immunohistochemistry as an adjunctive marker for the diagnosis of endometrial serous carcinoma"**
- **作者**: Zheng W, et al.
- **摘要**: 探讨IMP3抗体在子宫内膜浆液性癌诊断中的应用，显示IMP3高表达可作为鉴别高级别子宫内膜癌的辅助标志物。
3. **"The oncofetal protein IMP3: A novel molecular marker for predicting aggressive hepatocellular carcinoma"**
- **作者**: Wang T, et al.
- **摘要**: 通过组织芯片和IMP3抗体染色，证实IMP3在肝细胞癌中的表达与肿瘤侵袭性、转移及患者生存期缩短显著相关。
如需具体刊物或年份信息，可进一步补充关键词检索。
IMP3 (Insulin-like Growth Factor II mRNA-Binding Protein 3), also known as KOC (KH domain-containing protein overexpressed in cancer), is a member of the conserved IMP family of RNA-binding proteins involved in post-transcriptional gene regulation. Structurally, it contains six K-homology (KH) domains and two RNA recognition motifs (RRMs), enabling mRNA binding and modulation of translation, stability, or localization. IMP3 is predominantly expressed during embryonic development but shows minimal or absent expression in most normal adult tissues. However, its re-expression is frequently observed in various malignancies, including pancreatic, renal, hepatocellular, cervical, and ovarian cancers, where it correlates with aggressive tumor behavior and poor prognosis.
Functionally, IMP3 promotes tumor progression by enhancing cell proliferation, invasion, and metastasis while inhibiting apoptosis. Its role in stabilizing oncogenic mRNAs (e.g., IGF-II, MYC) and regulating alternative splicing underscores its pro-carcinogenic effects. IMP3 antibodies, widely used in immunohistochemistry (IHC), serve as critical diagnostic and prognostic tools. For instance, IMP3 positivity aids in distinguishing pancreatic ductal adenocarcinoma from benign lesions and predicts recurrence in renal cell carcinoma. Despite its diagnostic utility, IMP3's exact regulatory mechanisms remain under investigation, particularly its interplay with signaling pathways like Wnt/β-catenin. Ongoing research aims to explore IMP3 as a potential therapeutic target in precision oncology.
×
